Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Abstract
No trials have compared cabozantinib and regorafenib for the second-line treatment of advanced hepatocellular carcinoma (HCC). Conduct a matching-adjusted indirect comparison (MAIC) of the efficacy and safety of second-line cabozantinib and regorafenib in patients with advanced HCC and disease progression after prior sorafenib. The CELESTIAL and RESORCE trials were used for indirect comparison of second-line cabozantinib and regorafenib in...
Paper Details
Title
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Published Date
May 18, 2020
Journal
Volume
37
Issue
6
Pages
2678 - 2695
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History